Cetero Research, the CRO leader in the use of Environmental Exposure Chamber (EEC) technologies for asthma and allergy clinical research, has developed and validated two new EEC models. The first is a new cat allergen exposure chamber model that provides for study of therapeutics to treat perennial allergy and allergic asthma caused by exposure to living cats or aerosolized cat allergen in a controlled clinical setting. The second model for the study of dry eye provides pharmaceutical, biotechnology and device companies a consistent reproducible environment to study the effect of their product on signs and symptoms of dry eye.
“Our goal is to help our clients find accurate answers to development or marketing questions as quickly as possible,” said Dr. Alan Copa, President of Cetero’s Clinical Operations. “Like our other allergen models, these latest EEC models for cat dander and dry eye provide pharmaceutical and device companies with a cost-effective and faster alternative to traditional clinical trials. This chamber technology is in a highly-controlled clinical test environment governed by strict SOPs, creating conditions under which symptoms are induced reliably and data variability can be reduced.”
The EEC model is an established, regulatory-accepted clinical model that has been used for respiratory and immunology drug development for the past decade. Allergens studied in the EEC include ragweed, grass and tree pollens. Unlike traditional clinical trials, EEC studies can be run at any time of the year with highly consistent levels of pollen exposure.
“EEC models, including our newest cat allergen and dry-eye models, are ideal for proof-of-concept studies, phase II dose-ranging studies, onset and duration-of-action studies, combined pharmacokinetic and pharmacodynamic studies, prophylaxis and label-claim studies,” said Dr. Anne Marie Salapatek, Director of Research and Development for Cetero’s EEC. “We typically tailor the design of the study to meet the drug development needs of our clients. Designs can be remarkably flexible and can accommodate our clients’ goals and drugs with diverse mechanisms-of-action.” All EEC studies can be run in a turnkey, full-service fashion, taking advantage of Cetero’s strengths in data management, regulatory services, biostatistics and clinical monitoring.
Cetero differentiates itself by offering unique and sophisticated early clinical research techniques complemented by access to select patient populations in allergy, asthma, diabetes, obesity, renal and hepatic-impaired patients.
Cetero Research offers unmatched expertise in clinical pharmacology and bioanalytical with a foundation of more than 25 years of experience working with the biotechnology, generic and pharmaceutical industries.
About Cetero Research:
Cetero Research has the world’s largest capacity in six clinical pharmacology facilities focused on providing industry-leading early clinical development services, three bioanalytical laboratories and specialty phase II-IV services.Detailed company information is available at www.cetero.com, or by contacting April Johnson at 919.468.4214, or april.johnson@cetero.com.
Contacts:
Cetero Research
April Johnson, 919-468-4214
april.johnson@cetero.com